Latest / Pharmacy Podcast Network / The Latest Updates and Pharmacist Perspectives on RET Inhibitors in Non-Small Cell Lung Cancer | PTCE Pharmacy Connect
Transcript
- 0:07Speaker 1: Thanks for listening to the Pharmacy Podcast Network.
- 0:21Speaker 2: Hello and welcome to PTCEES Pharmacy Connect, a podcast focused
- 0:26Speaker 2: on continuing education created by pharmacists for pharmacists. PTC is
- 0:33Speaker 2: the leader in pharmacy and managed care education. In these episodes,
- 0:38Speaker 2: listeners will be presented with the most recent clinical updates
- 0:41Speaker 2: and strategies for implementing into practice and now Here's our
- 0:46Speaker 2: host and founder of the Pharmacy Podcast Network, Todd Yuri.
- 0:50Speaker 3: Welcome back to PTCEE Pharmacy Connect. My name's Todd Yuriy,
- 0:55Speaker 3: founder of the Pharmacy Podcast Network. So excited to have
- 0:59Speaker 3: the team coming back. We enjoy these podcasts. You might
- 1:03Speaker 3: be driving, you're walking, or doing something. Leave it to us.
- 1:06Speaker 3: There's going to be lots of notes and links in
- 1:09Speaker 3: your show notes that you can reference later. PTCEE Pharmacy
- 1:14Speaker 3: Connect is a powerful organization driving education through podcasting for
- 1:20Speaker 3: our pharmacists by pharmacists. Today is a great subject. I'd
- 1:24Speaker 3: like to introduce our moderator for today's podcast. Doctor Zara
- 1:28Speaker 3: Mahmood Jafari is the Clinical Pharmacy Manager, Division of Hematologic
- 1:34Speaker 3: Malatencies in Cellular Therapeutics at the University of Kansas Cancer
- 1:40Speaker 3: Center who will lead a great discussion on ret inhibitors
- 1:44Speaker 3: in non small cell lung cancer. Zara, how are you?
- 1:48Speaker 4: I'm great, Todd, how are you? Thank you so much.
- 1:50Speaker 4: I'm really happy to be here. I'm extremely excited to
- 1:55Speaker 4: be able to moderate today's session. Super thanks for Pharmacy
- 2:00Speaker 4: Times for having me, and it is no exception my
- 2:03Speaker 4: I think titles clearly gives it away that I am
- 2:06Speaker 4: not a lung cancer expert, so I'm actually going to
- 2:09Speaker 4: be learning right alongside our listeners today, so I'm really
- 2:15Speaker 4: excited to learn. I think I've gotten a small taste
- 2:18Speaker 4: of some more recent lung cancer updates in the realm
- 2:22Speaker 4: of bispecifics, but I know that the ret inhibitors are
- 2:25Speaker 4: also a hot topic of conversation and non small cell
- 2:28Speaker 4: lung cancer, so I'm really excited to introduce our faculty
- 2:32Speaker 4: with me today. Lauren Ledbetter, who is our clinical pharmacy
- 2:35Speaker 4: specialist at the Games at Ohio State University, who is
- 2:40Speaker 4: going to spend some time discussing the role of ret
- 2:42Speaker 4: inhibitors in the treatment of metastatic non small cell lung
- 2:45Speaker 4: cancer and then highlight the most common side effects. Hopefully
- 2:48Speaker 4: to be able to improve our patient's compliance because oral
- 2:51Speaker 4: chemotherapy and compliance go hand in hand and then overall tolerability. So, Lauren,
- 2:57Speaker 4: I would ask that you thank you so much for
- 3:01Speaker 4: being here, asked that you give a little bit of
- 3:03Speaker 4: background on yourself and your practice experience with this topic.
- 3:08Speaker 5: Yeah, thanks so much, Sarah, and to PTCE. I'm glad
- 3:11Speaker 5: to be here. So in terms of my career and
- 3:16Speaker 5: what's led me to this point, I've been a clinical
- 3:18Speaker 5: specialist now for the last almost ten years. I've had
- 3:22Speaker 5: my hand in practice at various medical oncology clinics, mostly
- 3:26Speaker 5: solid tumors. I spent four years at the VA treating
- 3:33Speaker 5: mostly lung cancer prostate cancer patients. That kind of did
- 3:37Speaker 5: a little bit of everything. But most recently my practice
- 3:41Speaker 5: has brought me to the James at Ohio State University,
- 3:45Speaker 5: and I'm the current pharmacy specialist and the thoracic medical
- 3:49Speaker 5: Oncology clinic.
- 3:50Speaker 4: Thanks so much for introducing yourself, Lauren. Fun fact and
- 3:53Speaker 4: you may not know this, Lauren, but I did my
- 3:55Speaker 4: PGI one at Ohio State. So I fell in love
- 3:58Speaker 4: with blood and mariat transplant at the James and was
- 4:03Speaker 4: really found my.
- 4:03Speaker 1: Life purpose there.
- 4:04Speaker 4: So I have a real soft spot for the team
- 4:07Speaker 4: at Ohio State. Of course, I've given myself away right
- 4:10Speaker 4: that I am in the blood and mara transplant space
- 4:13Speaker 4: as well as cell therapies now because those didn't exist
- 4:16Speaker 4: when I was in training. So I also understand that
- 4:20Speaker 4: with so much practice involvement, that has not been the exception.
- 4:25Speaker 4: In small and non small cell lung cancer, we know
- 4:27Speaker 4: that that has also experienced and evolved. But for our listeners,
- 4:31Speaker 4: can you give us a little bit of an overview
- 4:32Speaker 4: of non small cell lung cancer, including discussing what treatment
- 4:36Speaker 4: looked like for patients prior to these targeted therapies being available.
- 4:41Speaker 5: Right, Yeah, So, in terms of lung cancer in general,
- 4:47Speaker 5: you know, non small cell lung cancer is our main
- 4:51Speaker 5: type of lung cancer. It accounts for eighty five percent
- 4:55Speaker 5: of all lung cancer diagnoses, and then we have small
- 4:59Speaker 5: cell lung cancer, which accounts for roughly the remaining fifteen percent.
- 5:04Speaker 5: But as we're focusing on non small cell lung cancer
- 5:07Speaker 5: today with our ret inhibitor talk focusing specifically on the
- 5:12Speaker 5: predominant histologies of non small cell lung cancer, we have
- 5:17Speaker 5: our adnocarcinoma histology, which is the most common histology for
- 5:23Speaker 5: non small cell lung cancer. It accounts for roughly fifty
- 5:26Speaker 5: percent of our non small cell diagnoses, and then we
- 5:30Speaker 5: have squamas cell carcinoma that accounts for another thirty percent,
- 5:34Speaker 5: and then we have sort of various other histology types
- 5:37Speaker 5: that make up the remaining twenty ish percent. Prior to
- 5:42Speaker 5: the advent of targeted therapy and our first, our first
- 5:49Speaker 5: oral tyrosine kinase inhibitor, or TKI, was approved back in
- 5:54Speaker 5: twenty eleven chrisatine, which is an alk inhibitor that we'll
- 5:58Speaker 5: discuss briefly. But prior to that, we were primarily using
- 6:04Speaker 5: platinum based chemotherapies in this space. But these traditional chemotherapy
- 6:07Speaker 5: agents were very selective in their activity, so they're acting
- 6:12Speaker 5: on really any rapidly dividing cell, so not just the
- 6:15Speaker 5: cancer cell, but you know, hair gi tracts. So you know,
- 6:19Speaker 5: that's why historically patients have associated cancer treatment with you know,
- 6:25Speaker 5: horrible noge of vomiting, hair loss, things like that. But
- 6:29Speaker 5: what we did learn from patients with egfr al co
- 6:33Speaker 5: mutations and eventually re mutations, is that they've had historically
- 6:39Speaker 5: worse survival outcomes when they're treated with chemotherapy alone, when
- 6:43Speaker 5: you're comparing those patients against patients without any targetable mutations.
- 6:50Speaker 4: That's a lot of really great background. Thanks so much
- 6:52Speaker 4: for going over that when you were going through some
- 6:54Speaker 4: of the more traditional chemotherapies. That really rang a bell
- 6:57Speaker 4: with me and really resonated. I remember those, so I'm
- 7:00Speaker 4: not totally out of date. However, you know we still
- 7:04Speaker 4: use them. That's right, we still do. But to your point,
- 7:06Speaker 4: you know, I think having the ability to have more
- 7:10Speaker 4: targeted therapies has really allowed us individualized therapies. And you know,
- 7:15Speaker 4: and I again, it's been a minute since I've been
- 7:17Speaker 4: in PGUI two, but I do remember going through the
- 7:19Speaker 4: biology of cancer and learning about some of these targeted mutations.
- 7:23Speaker 4: So can you give us a little bit of background
- 7:26Speaker 4: and information about the specific mutations that are seen in
- 7:30Speaker 4: non small cell lung cancer.
- 7:33Speaker 5: Yeah, and I would say the targetable mutation sort of
- 7:37Speaker 5: arena within non small cell ung cancer has really grown
- 7:40Speaker 5: over the last twelve or so years. As I mentioned before,
- 7:44Speaker 5: we got our first targeted agent approved back in twenty
- 7:47Speaker 5: eleven with krasatneb for our ALC positive patients. But now
- 7:53Speaker 5: we have ten targetable mutations with at least twenty eight
- 7:58Speaker 5: FDA approved targeted agent supported by our NCCN guidelines, and
- 8:03Speaker 5: I actually I think number might be slightly higher because
- 8:06Speaker 5: we've just had a new agent approved in August for
- 8:10Speaker 5: DFR positive non small cell ung cancer. So I mean, honestly,
- 8:13Speaker 5: every month, I wouldn't be surprised that we see something
- 8:16Speaker 5: new coming out in this space. But most of the
- 8:20Speaker 5: targetable mutations for non small cell lung cancer patients are
- 8:23Speaker 5: going to be found in our patients with what we
- 8:25Speaker 5: call non squamous histology types. So the bulk of that,
- 8:30Speaker 5: like I said, would be an ad nocarcinoma histology. Occasually
- 8:35Speaker 5: we can find those on our weamous cell patients, especially
- 8:38Speaker 5: if our squeam of cell patients are never smokers or
- 8:42Speaker 5: have like a mixed histology type tumor where you have
- 8:46Speaker 5: like a little bit of ad nocarcinoma squamous cell at
- 8:50Speaker 5: play at the same time. And then if the biopsy
- 8:53Speaker 5: sample is too small to determine if it's one histology
- 8:58Speaker 5: or another, you know, some times can we can see
- 9:01Speaker 5: these mutations in our non squamous population. But overall, I
- 9:06Speaker 5: would say our most common mutation is the k r
- 9:10Speaker 5: Ass mutation. And that's about thirty percent of our patients.
- 9:16Speaker 5: That mutation in particular has historically predicted resistance to EGFR inhibitors.
- 9:23Speaker 5: But you know, other mutations that have been extensively studied,
- 9:27Speaker 5: we've found success with treatment using tyrosine kineses inhibitors. That
- 9:31Speaker 5: those listening in might have heard about include our EGFR
- 9:36Speaker 5: mutation that accounts to about fifteen percent of our patients.
- 9:43Speaker 5: And the other sort of mutation that I've hinted that
- 9:48Speaker 5: already is the ALK mutation or the anaplastic lymphoma kinas rearrangement,
- 9:53Speaker 5: and that's less common, that's around five percent of our patients. So,
- 9:58Speaker 5: you know, we've had the EGFR in the ALCAN mutations,
- 10:01Speaker 5: and we've had nearly you know, fifteen years of experience
- 10:04Speaker 5: with treating those mutations with their respective TKIs. But I
- 10:09Speaker 5: would say in the last five years or so, we've
- 10:12Speaker 5: further identified other targets and developed other new oral agents.
- 10:17Speaker 5: And I think a good example of that is is
- 10:19Speaker 5: our ret or rearranged during transfection gene rearrangements, and so
- 10:27Speaker 5: our ret is a tyrosine kind of receptor that affects
- 10:31Speaker 5: cellular proliferation and differentiation. So it kind of allows cancer
- 10:35Speaker 5: cells to continue to proliferate and almost kind of immortalize
- 10:38Speaker 5: the cancer cell, so it definitely makes it more difficult
- 10:42Speaker 5: to treat. The incidence is anywhere from one to two
- 10:47Speaker 5: percent in our non small cell on cancer patients, so
- 10:50Speaker 5: not a common mutation by any means, but still can
- 10:54Speaker 5: affect you know, thousands of patients a year they're diagnosed
- 10:57Speaker 5: with non small cell on cancer. Again mostly in non
- 11:02Speaker 5: smoker patients with an adnocarcinoma histology, though I do believe
- 11:08Speaker 5: there's some European data to suggest it can be found
- 11:10Speaker 5: in both smokers and non smokers, typically in females less
- 11:15Speaker 5: than sixty years of age, so just a little extra
- 11:18Speaker 5: information there.
- 11:20Speaker 4: Wow, I'm honestly really blown away. You know, obviously I've
- 11:23Speaker 4: only been following this a little bit more peripherally, just
- 11:28Speaker 4: given where the Dizzy states in which I cover, But
- 11:32Speaker 4: it's really incredible to see such innovation and really a small,
- 11:36Speaker 4: I mean not really a long period of time.
- 11:38Speaker 1: Twelve years is not that long.
- 11:40Speaker 4: And if you really think about it in terms of innovation,
- 11:44Speaker 4: and I definitely know as these have evolved, molecular testing
- 11:49Speaker 4: and targeted treatments are going hand in hand. So that
- 11:53Speaker 4: is a topic of conversation that's come up a lot
- 11:55Speaker 4: is making sure that patients are appropriately tested when they're diagnosed.
- 12:01Speaker 4: And so what would you kind of as a pharmacist
- 12:04Speaker 4: who works in this space recommend for pharmacists that are
- 12:07Speaker 4: maybe less familiar, what are what is it that they
- 12:10Speaker 4: need to know about, how these mutations are identified, and
- 12:13Speaker 4: then how we can make sure and help on our end.
- 12:16Speaker 4: We know we wear many hats and this is no exception,
- 12:18Speaker 4: So how do we know on our end how to
- 12:20Speaker 4: ensure appropriate patients are being tested right?
- 12:24Speaker 5: Right? And that's a that's an important point. You know,
- 12:26Speaker 5: if we can't test these patients, how are you going
- 12:29Speaker 5: to be able to treat them effectively? So we typically
- 12:33Speaker 5: go by the NCCN guidelines that recommend all patients that
- 12:38Speaker 5: are newly diagnosed, especially if you're diagnosed with advanced stage disease.
- 12:43Speaker 5: So definitely our metastatic patients, all of them be tested
- 12:48Speaker 5: for possible mutations and anything that could get you know,
- 12:51Speaker 5: have a drug target associated with that mutation with specifically
- 12:56Speaker 5: next generation sequencing techniques. I would say, you know, ideally
- 13:02Speaker 5: providers would have this information in hand before deciding on
- 13:06Speaker 5: a treatment pathway because like I mentioned before, this impacts
- 13:11Speaker 5: overall survival and patient response to initial therapy. So you know,
- 13:16Speaker 5: having that at hand when when making that treatment decisions important.
- 13:21Speaker 4: Okay, so let's take a moment and focus on the
- 13:24Speaker 4: rearrangement and non small cellung cancer. And you certainly spoke
- 13:28Speaker 4: to this a little bit in our first segment and
- 13:31Speaker 4: the fact that it affects only a small proportion of
- 13:33Speaker 4: non small cell on cancer patients compared to some of
- 13:35Speaker 4: our other mutations.
- 13:36Speaker 1: But I think due to the.
- 13:37Speaker 4: Large number of patients that are diagnosed each year in
- 13:39Speaker 4: the United States, that's still thousands of patients. And so
- 13:42Speaker 4: can you talk to us a little bit about the
- 13:44Speaker 4: first targeted agent for RET rearrangement positive non small cellung cancer.
- 13:49Speaker 5: Before twenty twenty, you know, we didn't really have any
- 13:52Speaker 5: one specific agent FDA approved for any of our RET
- 13:57Speaker 5: positive patients. So we had an article from Drilling at
- 14:04Speaker 5: All that looked at twenty five patients that had a
- 14:08Speaker 5: noted RET mutation as part of their non small cell
- 14:13Speaker 5: lung cancer. Seven of those twenty five patients, so twenty
- 14:19Speaker 5: eight percent, had a partial response to using cabo xantinib
- 14:24Speaker 5: sixty milligrams daily, which we've used in a variety of
- 14:27Speaker 5: other spaces. It helped a bit with the progression free
- 14:33Speaker 5: survival about five point five months, which was reasonable for
- 14:37Speaker 5: a second line agent in a metastatic setting at the time.
- 14:41Speaker 5: But one thing they did find was that seventy three
- 14:45Speaker 5: percent of those patients required a dose reduction to manage toxicities. Specifically,
- 14:51Speaker 5: you know, have hadotoxicity, some elevated light pace. Those were
- 14:55Speaker 5: probably the most common things they saw. Through this very
- 14:58Speaker 5: small study. We're getting really minimal benefit for a lot
- 15:02Speaker 5: of off target side effects. So there's definitely a lot
- 15:04Speaker 5: of room for improvement in this space.
- 15:09Speaker 4: And you know, to your point about toxicities, we have
- 15:11Speaker 4: a whole section coming up early to toxicities and how
- 15:14Speaker 4: important it is as pharmacists right to monitor and managers
- 15:18Speaker 4: these toxicities.
- 15:19Speaker 1: But kind of before we segue.
- 15:21Speaker 4: Into that, the FDA approved two medications for ret mutated tumors.
- 15:25Speaker 1: So can you tell us a little bit about.
- 15:26Speaker 4: The trials that led to those approvals specifically?
- 15:29Speaker 5: Sure, Yeah, The trials I'll talk about center around two
- 15:33Speaker 5: of our agents, sell per caten eb and palcentinib, and
- 15:38Speaker 5: I'll start with cell per cateneb first only because that
- 15:41Speaker 5: was the technically the first one approved by the FDA
- 15:45Speaker 5: back in twenty twenty, and this is specifically approved for
- 15:48Speaker 5: REP positive non small cell lung cancer as a first
- 15:52Speaker 5: line treatment option. The Librettos Or zero one study was
- 15:57Speaker 5: phase one and two study looked at one hundred and
- 16:02Speaker 5: five patients that had already had treatment with platinum based
- 16:05Speaker 5: chemotherapy and had progressed on that treatment, and then looked
- 16:09Speaker 5: at thirty nine patients who were treatment naive. The objective
- 16:12Speaker 5: response rate for patients who were using this as a
- 16:15Speaker 5: first line treatment option was about eighty five percent, so
- 16:18Speaker 5: you know, already we're improving on that data that we
- 16:20Speaker 5: saw with caves antoneb, and the progression pre survival at
- 16:25Speaker 5: least with the initial study hadn't been reached. And then
- 16:28Speaker 5: future updates with the study showed a progression pre survival
- 16:32Speaker 5: of twenty two months, so definitely improving on that five
- 16:36Speaker 5: point five months that we saw with cavias anteneb. And
- 16:40Speaker 5: then for those patients who were receiving sell per cat
- 16:44Speaker 5: neb as a second line treatment option, still saw a
- 16:47Speaker 5: beneficial objective response rate of sixty four percent and their
- 16:51Speaker 5: progression free survival is eighteen point four months. Another concern
- 16:56Speaker 5: with our patients with non small cell lung cancer are
- 16:58Speaker 5: our patients that do have CNS disease. So both Libretto
- 17:03Speaker 5: studies you know, enrolled patients with baseline CNS disease and
- 17:08Speaker 5: was you know, noted uh response rate of ninety one
- 17:13Speaker 5: percent in in the CNS, which is pretty significant and
- 17:21Speaker 5: and did maintain that response even in follow up. And
- 17:24Speaker 5: then finally the Libretto for three one study actually looked
- 17:29Speaker 5: at cel per cat NEB versus a platinum based chemo
- 17:34Speaker 5: with or without ammuno therapy in the first line setting exclusively,
- 17:39Speaker 5: and our data here for those patients. The progression free
- 17:42Speaker 5: survival of selper cat NEB was twenty four point eight
- 17:45Speaker 5: months versus eleven point two months with our with our
- 17:49Speaker 5: chemotherapy arm and an overall response rate of eighty four percent.
- 17:54Speaker 5: Her perspective here for for our our Keynote one eighty
- 17:58Speaker 5: nine trial would looked at platinum based chemo with pimberlismab
- 18:03Speaker 5: and all comers. Our progression free survival with our all
- 18:06Speaker 5: comer population with seventeen months. So we've taken patients with
- 18:10Speaker 5: our ret mutation given them sell per cat neb first
- 18:14Speaker 5: line and we have a progression free survival of twenty
- 18:16Speaker 5: four point eight months, so a lot to learn, especially
- 18:19Speaker 5: about the importance of using the right targeted therapy upfront
- 18:24Speaker 5: for all of these REP positive patients. Definitely came from
- 18:28Speaker 5: a lot of a lot of these studies and then
- 18:33Speaker 5: moving onto our preal SETNIB. It was approved in September
- 18:39Speaker 5: of twenty twenty, so it was only about four months
- 18:41Speaker 5: from the initial self per catineb approval. But this has
- 18:44Speaker 5: approved based on the Aero study, which was a phase
- 18:47Speaker 5: one and two study, so very similar to the librettos
- 18:50Speaker 5: erzer one design. The sel per cateneb but you know,
- 18:55Speaker 5: had ninety two patients that had previously received treatment with
- 18:59Speaker 5: a platinumased chemotherapy, twenty nine patients who are treatment naive.
- 19:04Speaker 5: So for those patients in the first line setting, they
- 19:06Speaker 5: noted an objective response rate of seventy percent, three of
- 19:10Speaker 5: those patients had a complete response, and then in the
- 19:14Speaker 5: second line setting an objective response rate of fifty nine
- 19:17Speaker 5: percent after their prior chemo and five of those patients
- 19:23Speaker 5: had a complete response. And again intracranial response was noted
- 19:28Speaker 5: in the PROW set and up study as well, So
- 19:30Speaker 5: seventy percent and ten patients that were enrolled with baseline
- 19:37Speaker 5: CNS disease.
- 19:38Speaker 4: I really appreciate you going through the background and some
- 19:41Speaker 4: of the pivotal trials that led to these products being approved,
- 19:44Speaker 4: and I do appreciate having options in our toolbox and
- 19:48Speaker 4: our toolkits. So let's transport our audience into a clinic
- 19:54Speaker 4: with you, and you have a newly diagnosed patient and clinic. Now,
- 19:58Speaker 4: given that you do have these options, how how would
- 20:01Speaker 4: you decide which therapy.
- 20:03Speaker 1: You're going to recommend?
- 20:04Speaker 4: And I know that you're going to answer this like
- 20:06Speaker 4: a pharmacist, so please try to give the audience some
- 20:10Speaker 4: thoughts and kind of what goes on in your decision
- 20:13Speaker 4: making when you're making these decisions.
- 20:15Speaker 5: Right, So, the NCCN lists self for katinab, prel setnab,
- 20:21Speaker 5: cata zant neb as options for first line or subsequent
- 20:27Speaker 5: line treatment. They don't really give a preference to any
- 20:30Speaker 5: one specific agent. They do note that while they don't
- 20:34Speaker 5: give preference to pre setna or self for catinb, they
- 20:37Speaker 5: do kind of denote that kaba xant nib may only
- 20:41Speaker 5: be used in certain circumstances. So generally, if we're presented
- 20:48Speaker 5: with a patient clinic with a retmutation, you know, we're
- 20:52Speaker 5: thinking either sulfur CATINB or pre SETNAB. From there, it
- 20:55Speaker 5: really just depends on the toxicity profile of each medication
- 20:59Speaker 5: and then comorbidities these patients have to help kind of
- 21:03Speaker 5: determine which one's the best fit.
- 21:05Speaker 4: So let's dive in now, and you kind of gave
- 21:07Speaker 4: us a little bit of information and maybe a teaser
- 21:11Speaker 4: of some of the adverse events related to these therapies.
- 21:13Speaker 4: So I'd really like to look into the adverse effects
- 21:15Speaker 4: of that are associated specifically with RET inhibitors.
- 21:19Speaker 1: Are there class effects associated with the agent's inhibiting RET.
- 21:22Speaker 1: I'll tell us a little bit more about that.
- 21:24Speaker 5: Yeah, So we've we've identified some sort of class effects
- 21:27Speaker 5: to RET that mostly we've found to be related to
- 21:31Speaker 5: the off target VEGEF effects that these are. These inhibitors
- 21:37Speaker 5: are also hitting things like hypertension, lead risk, decreased woond healing.
- 21:43Speaker 5: That's that's a class effect of the RET inhibitors. In
- 21:48Speaker 5: addition to have patotoxicity, hematologic toxicities, diarrhea and then edema
- 21:56Speaker 5: can also be another another class effect of the RET inhibitors.
- 22:01Speaker 4: Great, So that's good to know. I think it's important
- 22:05Speaker 4: for the pharmacists listening in to have a good understanding
- 22:08Speaker 4: of what those class effects look like. If we wanted
- 22:11Speaker 4: to dive in a little bit more deep into specific
- 22:14Speaker 4: agents the sell per catinet. For instance, when you are
- 22:17Speaker 4: counseling a patient as they're newly starting this, what are
- 22:21Speaker 4: some of the toxicities that you're making sure to focus
- 22:23Speaker 4: on that you know that you're not going to let
- 22:25Speaker 4: them leave without having talked to about the side effects.
- 22:29Speaker 1: And then what is your approach to monitoring as well?
- 22:31Speaker 5: Of course the class effects like hypertension and diarrhea and edema,
- 22:35Speaker 5: but then you know, let them know we're going to
- 22:37Speaker 5: be monitoring several different lab values with their liver function,
- 22:41Speaker 5: their cholesterol, and their and their CBC. And then we'll
- 22:46Speaker 5: also want to get an EKG as a baseline because
- 22:53Speaker 5: we would most likely want to avoid using philper catinem
- 22:56Speaker 5: and patients with a QTc greater than five hundred.
- 23:01Speaker 1: That's great.
- 23:02Speaker 4: How about other pearls that you can discuss related to
- 23:05Speaker 4: dosing and course. As a pharmacust, we have to know
- 23:08Speaker 4: and have a good understanding of potential drug drug interaction,
- 23:11Speaker 4: so specifically with self percatinate. What are some pearls that
- 23:14Speaker 4: you could share with our listeners?
- 23:17Speaker 5: Right, So, oddly, the dosing for self percatinate is weight based,
- 23:22Speaker 5: So for patients who are greater than fifty kilos, our
- 23:26Speaker 5: initial dose is one hundred and sixty milligrams twice a day,
- 23:30Speaker 5: with or without food, and then if they're less than
- 23:33Speaker 5: fifty kilos, the starting dose is one hundred and twenty
- 23:37Speaker 5: milligrams twice daily. It was previously only available as a
- 23:42Speaker 5: forty milligram and an eight hundred or an eighty milligram capsule,
- 23:45Speaker 5: but they've been reformulated recently, so now we have in
- 23:49Speaker 5: addition to the forty and eighty tablets, we also have
- 23:51Speaker 5: one hundred and twenty milligrams one hundred and sixty milligrams,
- 23:54Speaker 5: so that really helps with pillburden as well for these patients.
- 23:59Speaker 5: Because self per catinem is a major SIT three or
- 24:03Speaker 5: four substrate, you know, we'll want to avoid our moderate
- 24:09Speaker 5: and strong SIT three A four inhibitors and inducers because
- 24:12Speaker 5: we have so many patients on proton pump inhibitors. I
- 24:17Speaker 5: think it's important, especially for pharmacists out in the community,
- 24:19Speaker 5: if you notice that your patient has a PPI on
- 24:22Speaker 5: their medication list. This is something that we would ask
- 24:27Speaker 5: patients to either switch to an H two blocker or
- 24:34Speaker 5: a locally acting ant acid. But if you can't get
- 24:38Speaker 5: them off the proton pump inhibitor, we actually asked that
- 24:40Speaker 5: we have that the patients take their cell per catinem
- 24:43Speaker 5: with food if they are also taking a ppicon currently.
- 24:48Speaker 4: So I think it's a really important point that this
- 24:50Speaker 4: dosing is weight based. Is fairly rare for oral chemo
- 24:53Speaker 4: agents to be weight based dosing, so really important points
- 24:56Speaker 4: that you bring up. And we know pharmacists involvement in
- 25:00Speaker 4: and patients that are receiving oral chemotherapy leads to reduction
- 25:04Speaker 4: inside effects and really does promote really.
- 25:07Speaker 1: Strong patient adherents.
- 25:09Speaker 4: When we think about RET agents specifically, you know, we
- 25:12Speaker 4: know that again based on just a few of the
- 25:14Speaker 4: things you've talked about today, that a pharmacist has so
- 25:16Speaker 4: many opportunities to improve outcomes. So if we were to
- 25:20Speaker 4: segue to the other RET targeted agent, pro set NIB,
- 25:23Speaker 4: when you're counseling a patient on this agent, what toxicities
- 25:26Speaker 4: are you educating about? And help me walk me through
- 25:30Speaker 4: your approach to monitoring for this for this agent specifically.
- 25:34Speaker 5: So you'll see some of the same similar toxicities are
- 25:39Speaker 5: pro set nib. You know, we still want to keep
- 25:41Speaker 5: an eye on their liver function, monitor for any hematologic toxicities,
- 25:48Speaker 5: make sure they're monitoring their blood pressure. I think the
- 25:51Speaker 5: unique thing here with paral setnib is that it does
- 25:54Speaker 5: carry a risk for neumanitis, and that's particularly important for
- 25:58Speaker 5: patients who have received any radiation to the chest or
- 26:02Speaker 5: may receive in the future. But apart from that, I
- 26:05Speaker 5: would say the other key difference is that we don't
- 26:07Speaker 5: need a baseline EKG with prow setnib, but every other
- 26:11Speaker 5: monitoring parameter would be would be the same as we've
- 26:13Speaker 5: seen with cell per cat NEB.
- 26:15Speaker 4: Well, that's great, and I'm going to ask the same
- 26:17Speaker 4: questions related to dosing and drug drug interactions here. So
- 26:21Speaker 4: anything specific are pearls you would want the audience to
- 26:24Speaker 4: make sure that they remembered with pro setnip.
- 26:26Speaker 5: Yeah, So prol setnib, i'd say, you know, as opposed
- 26:29Speaker 5: to cell per CATINB, prol setenib is a once a
- 26:31Speaker 5: day dosing, in particular four hundred milligrams. Is you're starting
- 26:36Speaker 5: dose on an empty stomach, so cell per cat neb
- 26:39Speaker 5: twice a day with without food, prol setnib once a
- 26:42Speaker 5: day on an empty stomach. Also some drug drug interactions here,
- 26:48Speaker 5: there's you know, no concern for QTc prolongation with prol setneb,
- 26:53Speaker 5: and then no specific recommendations around dosing with our proton
- 26:59Speaker 5: pump inhibitor with pearl setnip in particular. Three A four
- 27:03Speaker 5: again plays another role in its metabolism, two D six
- 27:08Speaker 5: and then one A one.
- 27:10Speaker 1: That's a lot.
- 27:11Speaker 4: There's a lot of information, and I hate to put
- 27:14Speaker 4: you on the spot. And it is a podcast after all,
- 27:16Speaker 4: so it's it's kind of difficult. It's it's always so
- 27:18Speaker 4: nice to be able to see this and maybe a
- 27:20Speaker 4: more visual format. But for those of us that are
- 27:25Speaker 4: audio listeners, can you help us with comparing and contrasting
- 27:29Speaker 4: pro satnib and sell per catenib kind of quickly like
- 27:32Speaker 4: what are some of the key points that are really
- 27:33Speaker 4: making them different? I would love for you to kind
- 27:36Speaker 4: of summarize that for for our listeners, right of course.
- 27:39Speaker 5: So so if you're thinking in terms of toxicity, sell
- 27:43Speaker 5: per catinib can cause more dry mouth, can cause more rash,
- 27:46Speaker 5: and then, like I've mentioned several times and everybody should
- 27:50Speaker 5: remember this this point QTc prolongation. And then I would
- 27:54Speaker 5: say overall, in terms of side effects, pearl setnib may
- 27:59Speaker 5: cause more GI shoes. And then if you're taking taking
- 28:03Speaker 5: the dosing into consideration again, palsetniv once daily on an
- 28:08Speaker 5: empty stomach, sell per cat and eb toys daily. And
- 28:12Speaker 5: then we also have to make sure, you know, we
- 28:14Speaker 5: have a weight available for the patient to for that
- 28:18Speaker 5: initial dose.
- 28:20Speaker 4: Yeah, thanks for taking a moment to summarize. I think
- 28:23Speaker 4: that's really important to call out. And as we as
- 28:26Speaker 4: we think about all these different side effects, and we
- 28:28Speaker 4: know that our pharmacist are integral and helping manage some
- 28:31Speaker 4: of these more common adverse events, how how can the
- 28:35Speaker 4: pharmacist help manage with these side effects that are specifically
- 28:39Speaker 4: associated with the ret inhibitors right?
- 28:42Speaker 5: Well, And as you've mentioned, you know several times, you know,
- 28:44Speaker 5: pharmacists sometimes can be your first line between the patient
- 28:49Speaker 5: and you know, any side effect that they may be experiencing.
- 28:53Speaker 5: So you know, hypertension is common with both of the medications,
- 28:57Speaker 5: So you know, if you're interacting with a physician and
- 29:01Speaker 5: you're trying to start therapy, making sure you know a
- 29:03Speaker 5: patient already has their blood pressure controlled at baseline, and
- 29:08Speaker 5: then regardless of whether or not they're already on any
- 29:11Speaker 5: anti hypertensives, they probably should be monitoring their blood pressure
- 29:14Speaker 5: at home at least for the first week of starting
- 29:18Speaker 5: therapy and making sure they have access to a blood
- 29:22Speaker 5: pressure cuff to be able to do that. And then
- 29:25Speaker 5: for those patients who we do start to notice some
- 29:28Speaker 5: consistent elevated blood pressure readings, we may need to either
- 29:35Speaker 5: start an anti hypertensive if they're naive, or optimize what
- 29:38Speaker 5: they're currently on. And then lastly, diarrhea is another common
- 29:43Speaker 5: toxicity for both of their rat agents, So you know,
- 29:47Speaker 5: there's a several non pharmacologic recommendations we can make, you know,
- 29:51Speaker 5: making sure they're eating small meals, drinking plenty of water
- 29:54Speaker 5: so they're not getting dehydrated, using a brat diet, and
- 30:00Speaker 5: then having a recommendation for how to use a moodium
- 30:06Speaker 5: at home. But I think it's really important for the
- 30:10Speaker 5: patient to have really good communication with their providers so
- 30:12Speaker 5: they can let them know how their diarrhea is being
- 30:17Speaker 5: controlled and if they're having any signs of dehydration. But
- 30:24Speaker 5: if you're looking at the package insert for both PROW
- 30:27Speaker 5: sententive and self or katina. There aren't any specific dose
- 30:31Speaker 5: adjustments for diarrhea in particular, but they do kind of
- 30:36Speaker 5: leave it open ended for holds and recommended dose adjustments
- 30:41Speaker 5: for any grade three or four side effects that are
- 30:44Speaker 5: likely attributable to the medication. But when you think about it,
- 30:49Speaker 5: grade three diarrhea is considered to be an increase of
- 30:53Speaker 5: several more stools from their baseline, and that's kind of
- 30:56Speaker 5: a lot to ask for a patient to endure before you,
- 31:00Speaker 5: you know, potentially reduce or hold their medication. So I
- 31:03Speaker 5: would say, you know, package inserts are great references, but
- 31:07Speaker 5: they shouldn't be any substitute for clinical judgment. So if
- 31:11Speaker 5: you think that a patient is still deriving benefit from
- 31:13Speaker 5: a ret inhibitor and we may be able to help
- 31:16Speaker 5: control side effects like diarrhea with a hold even if
- 31:22Speaker 5: they're not yet considered grade three, I think that's that's
- 31:27Speaker 5: up to the physician and the patient to discuss. But
- 31:30Speaker 5: I do think it's an option. We've done that a
- 31:32Speaker 5: few times in some of the patients we've seen in
- 31:34Speaker 5: my clinic, So.
- 31:35Speaker 4: I really appreciate you going through you know the background
- 31:38Speaker 4: on non smallclung cancer, some of the information related to
- 31:41Speaker 4: the ret inhibitors and their toxicities and how performances can
- 31:44Speaker 4: stay involved and integrated within this work. And it sounds
- 31:47Speaker 4: like and we've seen and appreciated so much innovation in
- 31:50Speaker 4: a short period of time, but what can we expect
- 31:53Speaker 4: with ret inhibitors in the non smalcalon cancer space in
- 31:56Speaker 4: the future.
- 31:58Speaker 5: Right so on the horizon, and we have the accelera
- 32:01Speaker 5: ret study, which is an ongoing phase three study that
- 32:06Speaker 5: compares preal setnib in the first line for the treatment
- 32:11Speaker 5: of metastatic ret positive non small cell lung cancer versus
- 32:15Speaker 5: chemo with pembrilism ab. So a very similar setup and
- 32:20Speaker 5: designed to that libretto for three one that we saw
- 32:23Speaker 5: with sell per cat nib in the first line setting.
- 32:28Speaker 5: I believe it's expected to be completed June of twenty
- 32:31Speaker 5: twenty five and their primary endpoint will be progression pre survival.
- 32:37Speaker 5: But ultimately this will give us that phase three data
- 32:42Speaker 5: for the use of prel setnib in the first line setting.
- 32:45Speaker 4: Thank you so much for your expertise and giving the
- 32:50Speaker 4: audience a chance to learn from you. Is if they
- 32:54Speaker 4: let's say they just tuned in and they wanted to
- 32:58Speaker 4: know the single most important takeaway, or our pharmacist a
- 33:01Speaker 4: listening and what would you say the single most important
- 33:03Speaker 4: takeaway was?
- 33:04Speaker 5: Yeah, so I would say, you know, for those firms
- 33:06Speaker 5: who have sort of a patient forward component to their practice,
- 33:12Speaker 5: the ability to identify adverse reactions to our ret inhibitors
- 33:17Speaker 5: and then help provide management recommendations and potentially even future
- 33:22Speaker 5: dose adjustments if we're reinitiating therapy or are the key
- 33:26Speaker 5: takeaways from our talk today.
- 33:31Speaker 1: Thank you so much, Lauren.
- 33:32Speaker 4: I cannot say how much how I've definitely enjoyed this
- 33:37Speaker 4: and learned a lot. And like I said at the
- 33:39Speaker 4: beginning of our time together, I was going to be
- 33:42Speaker 4: learning right alongside the audience, and so I can certainly
- 33:46Speaker 4: appreciate the innovation that has come in this very important
- 33:51Speaker 4: area of oncology in a short period of time. I
- 33:54Speaker 4: would not say that I could cover for you anytime soon,
- 33:57Speaker 4: but I at least have a little bit more information
- 33:59Speaker 4: than when we started, and I hope that the team
- 34:02Speaker 4: listening in has left with a few pearls and things
- 34:04Speaker 4: to think about. I'm excited to see how this space
- 34:09Speaker 4: evolves and how pharmacists can continue to stay as strong
- 34:15Speaker 4: advocates for patients in this space. So with that, I'd
- 34:18Speaker 4: like to like to thank the Pharmacy Podcast Network and
- 34:22Speaker 4: PTCE for having us both on today and really appreciate
- 34:26Speaker 4: everyone's attention and listening in.
- 34:28Speaker 1: Thanks so much, Thank.
- 34:30Speaker 3: You Lauren and Zara, this was an amazing conversation. We
- 34:35Speaker 3: want to shout out to all of our pharmacist listeners.
- 34:39Speaker 3: Take a look at all of PTCE Pharmacy Connects content.
- 34:43Speaker 3: There's so much there for you to learn from. Reach
- 34:46Speaker 3: out to the organization if you think there is a
- 34:49Speaker 3: subject that you'd like to hear covered, and if you
- 34:52Speaker 3: want to become involved, please once again also reach out
- 34:56Speaker 3: to PTCE Pharmacy Connect. We can get you involved in
- 35:00Speaker 3: the next PTCE Pharmacy Connect podcast.
- 35:07Speaker 2: Thanks for tuning in to the PTCEE Pharmacy Connect Podcast.
- 35:11Speaker 2: Your feedback is important to us. Please share with us
- 35:15Speaker 2: your thoughts on this episode and other topics you'd like.
- 35:17Speaker 1: To learn about.
- 35:19Speaker 2: Go to Pharmacytimes dot org, forward slash contact and send
- 35:24Speaker 2: us a message